Gates, all of your questions could and should be topics of a quarterly review for investors, some of the details of the science developments may need to remain hidden, but the business surrounding the science certainly could be openly reviewed quarterly for investors, and in addition, some of the science could be updated for investors as well, just not at revealing levels interfering with existing NDA's, more cursory level for investors